Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, April 14, 2022
[ Thu, Apr 14th 2022
] - WOPRAI
Wed, April 13, 2022
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
[ Wed, Apr 13th 2022
] - WOPRAI
David Lebowitz Maintained (BPMC) at Hold with Decreased Target to $68 on, Apr 13th, 2022
David Lebowitz of Citigroup, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $71 to $68 on, Apr 13th, 2022.
David has made no other calls on BPMC in the last 4 months.
There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022
These are the ratings of the 3 analyists that currently disagree with David
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
